GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2

被引:100
|
作者
Biosa, Alice [1 ,2 ]
Trancikova, Alzbeta [1 ]
Civiero, Laura [3 ]
Glauser, Liliane [1 ]
Bubacco, Luigi [3 ]
Greggio, Elisa [3 ]
Moore, Darren J. [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Brain Mind Inst, Sch Life Sci, CH-1015 Lausanne, Switzerland
[2] Univ Sassari, Sch Med, Dept Clin & Expt Med, I-07100 Sassari, Italy
[3] Univ Padua, Dept Biol, I-35121 Padua, Italy
基金
瑞士国家科学基金会;
关键词
ROC DOMAIN; GENE LRRK2; PROTEIN; MUTATIONS; BINDING; PHOSPHORYLATION; REVEALS; DIMER;
D O I
10.1093/hmg/dds522
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the LRRK2 gene cause autosomal dominant Parkinson's disease. LRRK2 encodes a multidomain protein containing a Ras-of-complex (Roc) GTPase domain, a C-terminal of Roc domain and a protein kinase domain. LRRK2 can function as a GTPase and protein kinase, although the interplay between these two enzymatic domains is poorly understood. Although guanine nucleotide binding is critically required for the kinase activity of LRRK2, the contribution of GTP hydrolysis is not known. In general, the molecular determinants regulating GTPase activity and how the GTPase domain contributes to the properties of LRRK2 remain to be clarified. Here, we identify a number of synthetic missense mutations in the GTPase domain that functionally modulate GTP binding and GTP hydrolysis and we employ these mutants to comprehensively explore the contribution of GTPase activity to the kinase activity and cellular phenotypes of LRRK2. Our data demonstrate that guanine nucleotide binding and, to a lesser extent, GTP hydrolysis are required for maintaining normal kinase activity and both activities contribute to the GTP-dependent activation of LRRK2 kinase activity. Guanine nucleotide binding but not GTP hydrolysis regulates the dimerization, structure and stability of LRRK2. Furthermore, GTP hydrolysis regulates the LRRK2-dependent inhibition of neurite outgrowth in primary cortical neurons but is unable to robustly modulate the effects of the familial G2019S mutation. Our study elucidates the role of GTPase activity in regulating kinase activity and cellular phenotypes of LRRK2 and has important implications for the validation of the GTPase domain as a molecular target for attenuating LRRK2-mediated neurodegeneration.
引用
收藏
页码:1140 / 1156
页数:17
相关论文
共 50 条
  • [31] Inhibition of LRRK2 Kinase Activity in the Treatment of Crohn's Disease
    Deloer, Sharmina
    Fuss, Ivan
    Suebsuwong, Chalada
    Kumar, Kunal
    Devita, Robert J.
    Peter, Inga
    Strober, Warren
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [32] Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
    Galatsis, Paul
    Henderson, Jaclyn
    Kormos, Bethany L.
    Hirst, Warren D.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 43 - 58
  • [33] Functional interaction of Parkinsons disease-associated LRRK2 with members of the dynamin GTPase superfamily
    Stafa, Klodjan
    Tsika, Elpida
    Moser, Roger
    Musso, Alessandra
    Glauser, Liliane
    Jones, Amy
    Biskup, Saskia
    Xiong, Yulan
    Bandopadhyay, Rina
    Dawson, Valina L.
    Dawson, Ted M.
    Moore, Darren J.
    HUMAN MOLECULAR GENETICS, 2014, 23 (08) : 2055 - 2077
  • [34] The role of LRRK2 in regulating microglial activity in Parkinson's disease (PD)
    Brooker, S.
    Thomas, A.
    Krainc, D.
    MOVEMENT DISORDERS, 2024, 39 : S417 - S418
  • [35] Characterization of LRRK2 kinase activity
    Ryder, J. W.
    Anderson, B. D.
    Huss, K. A.
    Wang, X.
    Qian, Y. -W.
    Campbell, R. M.
    Merchant, K. M.
    MOVEMENT DISORDERS, 2008, 23 (01) : S29 - S30
  • [36] A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2
    Dederer, Verena
    Murillo, Marta Sanz
    Karasmanis, Eva P.
    Hatch, Kathryn S.
    Chatterjee, Deep
    Preuss, Franziska
    Azeez, Kamal R. Abdul
    Nguyen, Landon Vu
    Galicia, Christian
    Dreier, Birgit
    Plueckthun, Andreas
    Versees, Wim
    Mathea, Sebastian
    Leschziner, Andres E.
    Reck-Peterson, Samara L.
    Knapp, Stefan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (07)
  • [37] The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
    Gloeckner, CJ
    Kinkl, N
    Schumacher, A
    Braun, RJ
    O'Neill, E
    Meitinger, T
    Kolch, W
    Prokisch, H
    Ueffing, M
    HUMAN MOLECULAR GENETICS, 2006, 15 (02) : 223 - 232
  • [38] Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
    Steger, Martin
    Tonelli, Francesca
    Ito, Genta
    Davies, Paul
    Trost, Matthias
    Vetter, Melanie
    Wachter, Stefanie
    Lorentzen, Esben
    Duddy, Graham
    Wilson, Stephen
    Baptista, Marco A. S.
    Fiske, Brian K.
    Fell, Matthew J.
    Morrow, John A.
    Reith, Alastair D.
    Alessi, Dario R.
    Mann, Matthias
    ELIFE, 2016, 5
  • [39] Search for potential targets of LRRK2 kinase associated with Parkinson disease
    Ziganshin, R.
    Lebedeva, O.
    Azarkin, I.
    Lagarkova, M.
    FEBS OPEN BIO, 2018, 8 : 154 - 154
  • [40] Leukocyte MAPK activity associated with the LRRK2 G2019S mutation and Parkinson's disease
    Aasly, Jan O.
    Toft, Mathias
    Kvam, Sylvia N.
    Farrer, Matthew J.
    White, Linda R.
    ANNALS OF NEUROLOGY, 2006, 60 : S9 - S9